PIQ Stock Overview Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Proteomics International Laboratories Ltd Competitors Price History & Performance
Summary of share price highs, lows and changes for Proteomics International Laboratories Historical stock prices Current Share Price AU$0.64 52 Week High AU$1.40 52 Week Low AU$0.55 Beta 0.49 1 Month Change -5.88% 3 Month Change -2.29% 1 Year Change -23.81% 3 Year Change -43.86% 5 Year Change 132.73% Change since IPO 184.44%
Recent News & Updates
Consensus revenue estimates fall by 34% Sep 12
New major risk - Financial position Sep 11
Full year 2024 earnings: EPS and revenues exceed analyst expectations Aug 23
Proteomics International Laboratories Ltd, Annual General Meeting, Nov 01, 2024 Aug 23
Proteomics International Laboratories Ltd Announces Resignation of Robyn Elliott as Non-Executive Director Aug 12
No longer forecast to breakeven Jun 17 See more updates
Consensus revenue estimates fall by 34% Sep 12
New major risk - Financial position Sep 11
Full year 2024 earnings: EPS and revenues exceed analyst expectations Aug 23
Proteomics International Laboratories Ltd, Annual General Meeting, Nov 01, 2024 Aug 23
Proteomics International Laboratories Ltd Announces Resignation of Robyn Elliott as Non-Executive Director Aug 12
No longer forecast to breakeven Jun 17
New minor risk - Profitability Feb 24 Proteomics International Laboratories Limited has filed a Follow-on Equity Offering in the amount of AUD 6.504 million. Proteomics International Laboratories Limited has filed a Follow-on Equity Offering. Jan 23
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable Nov 16
New major risk - Financial position Oct 02
Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ) Sep 29
High number of new and inexperienced directors Sep 29
Proteomics International Laboratories Limited, Annual General Meeting, Nov 23, 2023 Aug 22
New minor risk - Financial position Aug 22
Full year 2023 earnings: EPS and revenues miss analyst expectations Aug 22
We're Hopeful That Proteomics International Laboratories (ASX:PIQ) Will Use Its Cash Wisely May 10
First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.03 loss in 1H 2022) Mar 04
Proteomics International Laboratories Ltd Announces the Achievement of a Major Milestone in the Commercialisation of the PromarkerD Predictive Test for Diabetic Kidney Disease with the Approval of a New Dedicated CPT Proprietary Laboratory Analyses (PLA) Code for the Test in the United States Jan 03
Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being Nov 17
High number of new and inexperienced directors Nov 16
Proteomics International Laboratories Ltd Secures A Patent in Hong Kong for PromarkerD, First Predictive Diagnostic Test for Diabetic Kidney Disease Nov 12
Independent Non-Executive Director exercised options to buy AU$90k worth of stock. Oct 25
Proteomics International Laboratories Limited Announces Its Prototype Diagnostic Test for Oesophageal Adenocarcinoma Demonstrates Strong Diagnostic Performance Sep 28
Full year 2022 earnings released: AU$0.05 loss per share (vs AU$0.028 loss in FY 2021) Aug 31
Proteomics International Laboratories Limited, Annual General Meeting, Nov 24, 2022 Aug 30 Proteomics International Laboratories Limited announced that it expects to receive AUD 7.9985 million in funding Aug 16
Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth? Aug 09 Proteomics International Laboratories Limited Announces Clinical Utility Study Demonstrates PromarkerD Test Offers Improved Treatment Options for Doctors in the Fight Against Diabetic Kidney Disease
Proteomics International Laboratories Limited Completes the Initial Analysis of Its Endometriosis Clinical Validation Study Aimed At Diagnosing the Gynaecological Condition Using A Simple Blood Test Jul 01
Proteomics International Laboratories Limited Successfully Produce A Pilot Batch of PromarkerD Test Components with Specialist Immunoassay Manufacturer Biotem Jun 16
Proteomics International Laboratories Limited Study Shows PromarkerD also Predicts Late-Stage Renal Issues Jun 07
Proteomics International Laboratories Limited Announces PromarkerD Registration Submitted to the TGA Jun 04
High number of new and inexperienced directors Jun 01
High number of new and inexperienced directors May 02
Proteomics International Laboratories Limited Announces New Clinical Advisory Board Apr 12
First half 2022 earnings: Revenues and EPS in line with analyst expectations Mar 02
Proteomics International Laboratories Limited Completes Pre-Assessment Phase of PromarkerD Feb 22
Proteomics International Laboratories Limited Identifies Novel Biomarkers for Asthma and COPD Feb 07
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26 Shareholder Returns PIQ AU Life Sciences AU Market 7D -2.3% 0.6% -2.0% 1Y -23.8% 12.0% 7.8%
See full shareholder returns
Return vs Market: PIQ underperformed the Australian Market which returned 7.8% over the past year.
Price Volatility Is PIQ's price volatile compared to industry and market? PIQ volatility PIQ Average Weekly Movement 8.9% Life Sciences Industry Average Movement 8.9% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: PIQ has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PIQ's weekly volatility (9%) has been stable over the past year.
About the Company Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment.
Show more Proteomics International Laboratories Ltd Fundamentals Summary How do Proteomics International Laboratories's earnings and revenue compare to its market cap? PIQ fundamental statistics Market cap AU$83.84m Earnings (TTM ) -AU$6.38m Revenue (TTM ) AU$3.28m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PIQ income statement (TTM ) Revenue AU$3.28m Cost of Revenue AU$2.02m Gross Profit AU$1.26m Other Expenses AU$7.64m Earnings -AU$6.38m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.049 Gross Margin 38.49% Net Profit Margin -194.62% Debt/Equity Ratio 0%
How did PIQ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 18:18 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Proteomics International Laboratories Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Iain Wilkie Morgans Financial Limited
Show 0 more analysts 
